Anticonvulsants

1. THE 2-MINUTE PHYSIOLOGY (Rapid Pathophysiology)

• Phenytoin: Toxicity is driven by dose-dependent blockade of voltage-gated sodium channels. Notably, phenytoin exhibits zero-order (saturation) kinetics at higher therapeutic or toxic doses, meaning a small increase in dose can lead to a massive, prolonged spike in serum levels and severe cerebellar/vestibular dysfunction (nystagmus, ataxia). Furthermore, the IV formulation contains propylene glycol as a diluent, which acts as a direct myocardial depressant and vasodilator.
• Carbamazepine: Structurally related to tricyclic antidepressants (TCAs). Toxicity is driven by fast sodium channel blockade in the myocardium and profound anticholinergic effects in the central and peripheral nervous systems.
• Valproic Acid (VPA): Increases GABA levels. In severe overdose, VPA metabolites deplete endogenous carnitine. Without carnitine, fatty acids cannot enter the mitochondria for beta-oxidation, halting the urea cycle. This specific breakdown results in massive hyperammonemia, hepatotoxicity, and subsequent cerebral edema.

2. THE BEDSIDE ACTION PLAN (Rapid ER Management)

• Immediate Stabilization (ABCD3EF): Secure the airway, establish bilateral IV access, and initiate continuous cardiac and pulse oximetry monitoring.
• Gastrointestinal Decontamination: If the patient presents within 1 hour of ingestion with a protected airway, administer activated charcoal. Multi-Dose Activated Charcoal (MDAC) is uniquely indicated for severe carbamazepine and phenytoin toxicity because they undergo extensive enterohepatic recirculation and have delayed gastrointestinal absorption.
• Agent-Specific Antidotal Therapy:
• Valproic Acid Toxicity: For patients with VPA-induced hyperammonemic encephalopathy or hepatotoxicity, administer Levocarnitine (L-carnitine). Dose: 100 mg/kg IV over 30 minutes, followed by 15 mg/kg every 4 hours.
• Carbamazepine Toxicity: If the ECG demonstrates a widened QRS complex (> 100 msec), push Sodium Bicarbonate 1-2 mEq/kg IV to overcome the sodium channel blockade.
• Hemodynamic Management: Treat IV phenytoin-induced hypotension with immediate cessation of the infusion and IV crystalloid boluses.

3. THE DIAGNOSTIC GRID (Differential Diagnosis & Workup)

• The "Can't-Miss" Mimics:
• Acute Alcohol Intoxication/Withdrawal: Mimics the ataxia, nystagmus, and altered mental status seen in anticonvulsant toxicity.
• Wernicke's Encephalopathy: Presents with ataxia, confusion, and nystagmus (the classic triad), mimicking phenytoin toxicity.
• TCA Toxicity: Mimics carbamazepine toxicity perfectly (wide QRS, anticholinergic toxidrome, seizures).
• CNS Infection/Space Occupying Lesion: Can present with altered mental status and seizures.
• Prioritized Diagnostic Workup:
• STAT Anticonvulsant Levels: Obtain quantitative serum levels of phenytoin, carbamazepine, and valproic acid.
• Ammonia Level & LFTs: Mandatory in any patient presenting with VPA ingestion or undifferentiated lethargy.
• Basic Metabolic Panel & VBG: Assess for anion gap metabolic acidosis and electrolyte derangements.
• 12-Lead ECG: Critical to assess for conduction delays.

4. THE VISUAL BOARD (ECG / POCUS / Imaging)

• 12-Lead ECG:
• For carbamazepine toxicity, scrutinize the ECG for QRS widening (>100 ms) and a prominent terminal R wave in lead aVR (>3 mm), indicative of sodium channel blockade.
• For IV phenytoin toxicity, look for profound bradycardia, AV blocks, or QT prolongation.
• Physical Examination: Look for the classic triad of phenytoin toxicity: multi-directional nystagmus, dysarthria, and severe ataxia.
• CT Head: Obtain a non-contrast head CT in any comatose patient or a patient with persistent focal deficits to rule out an acute intracranial hemorrhage or cerebral edema (especially in VPA toxicity).

5. THE SCORING MATRIX (Risk Stratification & Guidelines)

• General Disposition Guidelines: Patients with stable vital signs, resolution of post-ictal or drug-related sedation, and therapeutic anticonvulsant levels can be discharged home after consultation with toxicology. Patients with unstable vital signs, persistent ataxia, vomiting, or new laboratory abnormalities (e.g., elevated LFTs or hyperammonemia) mandate hospital admission.
• Extracorporeal Removal (Dialysis) Criteria:
• Valproic Acid: Hemodialysis is definitively indicated for serum levels > 900 mg/L, or > 1300 mg/L if the patient is in shock, or if there is any clinical evidence of cerebral edema.
• Carbamazepine: High-flux hemodialysis or charcoal hemoperfusion is indicated for refractory seizures, life-threatening dysrhythmias, or extreme serum levels.

6. THE DANGER ZONE (Pitfalls & Critical Actions)

• The Phenytoin Administration Trap: Pitfall: Pushing IV phenytoin faster than 50 mg/min. Critical Action: Rapid infusion causes severe hypotension and bradyarrhythmias due to the propylene glycol diluent. It can also cause severe tissue necrosis ("Purple Glove Syndrome") if extravasation occurs. Always use fosphenytoin if rapid IV loading is required.
• The Normal LFT Blindspot: Pitfall: Ruling out VPA toxicity because hepatic transaminases are normal. Critical Action: VPA-induced hyperammonemic encephalopathy can occur with completely normal LFTs. You must specifically order a serum ammonia level.
• The Isoniazid Seizure Trap: Pitfall: Treating seizures caused by INH toxicity with standard phenytoin. Critical Action: INH seizures are refractory to phenytoin. They strictly require Pyridoxine (Vitamin B6).

7. MCQ MASTERCLASS (Written Exam Tips)

• Buzzword: “Purple Glove Syndrome” → Exam Answer: Extravasation of intravenous phenytoin. (Alternative safer agent: Fosphenytoin).
• Buzzword: “Patient on seizure medication presents with lethargy, normal LFTs, and an ammonia level of 150” → Exam Answer: Valproic acid toxicity. The treatment is IV L-carnitine.
• Classic Presentation: An epileptic patient presents with horizontal and vertical nystagmus, a broad-based staggering gait (ataxia), and slurred speech. → Exam Answer: Phenytoin toxicity.
• Distractor Option: "Treat carbamazepine-induced QRS widening with amiodarone." Correction: Incorrect. Carbamazepine acts like a TCA; treating the sodium channel blockade with amiodarone exacerbates the cardiotoxicity. The correct answer is Sodium Bicarbonate.

8. THE BOARDROOM SCRIPT (OSCE & Oral Board Tips)

• The Initial Resuscitation: "The patient is presenting with altered mental status, ataxia, and nystagmus. I will immediately place the patient on a cardiac monitor, establish bilateral IV access, and check a STAT point-of-care glucose. I am evaluating the airway for protection and will secure it if the GCS drops below 8."
• The Diagnostic Workup: "Given the suspicion of anticonvulsant toxicity, I am ordering quantitative serum levels of phenytoin, valproic acid, and carbamazepine, along with a CMP, LFTs, and a serum ammonia level. I will obtain a 12-lead ECG to evaluate for QRS widening indicative of sodium channel blockade."
• Targeted Treatment & Disposition: "The ECG shows a widened QRS; I will immediately push 2 ampules of sodium bicarbonate. For the elevated VPA and ammonia levels causing encephalopathy, I am ordering IV L-carnitine. I will consult Medical Toxicology for recommendations on Multi-Dose Activated Charcoal and prepare the patient for admission to the intensive care unit."